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Comparison of nanoparticular 
hydroxyapatite pastes of different 
particle content and size in a novel 
scapula defect model
Veronika Hruschka1,2, Stefan Tangl2,3, Yulia Ryabenkova4, Patrick Heimel1,2,3, Dirk Barnewitz5, 
Günter Möbus4, Claudia Keibl1,2, James Ferguson1,2, Paulo Quadros6, Cheryl Miller7, 
Rebecca Goodchild8, Wayne Austin8, Heinz Redl1,2 & Thomas Nau1,2
Nanocrystalline hydroxyapatite (HA) has good biocompatibility and the potential to support bone 
formation. It represents a promising alternative to autologous bone grafting, which is considered the 
current gold standard for the treatment of low weight bearing bone defects. The purpose of this study 
was to compare three bone substitute pastes of different HA content and particle size with autologous 
bone and empty defects, at two time points (6 and 12 months) in an ovine scapula drillhole model 
using micro-CT, histology and histomorphometry evaluation. The nHA-LC (38% HA content) paste 
supported bone formation with a high defect bridging-rate. Compared to nHA-LC, Ostim® (35% HA 
content) showed less and smaller particle agglomerates but also a reduced defect bridging-rate due to 
its fast degradation The highly concentrated nHA-HC paste (48% HA content) formed oversized particle 
agglomerates which supported the defect bridging but left little space for bone formation in the defect 
site. Interestingly, the gold standard treatment of the defect site with autologous bone tissue did not 
improve bone formation or defect bridging compared to the empty control. We concluded that the 
material resorption and bone formation was highly impacted by the particle-specific agglomeration 
behaviour in this study.
Autologous bone graft is considered the gold standard for the treatment of low weight-bearing bone defects. 
Autologous bone grafts have osteogenic, osteoinductive and osteoconductive properties while being non immu-
nogenic. However, complications at the graft harvesting site, including infection, prolonged wound drainage, 
large hematomas, vascular injuries, the need for revision surgery, pain, sensory loss, herniation, fracture and 
cosmetically problematic scars may occur1–7. Synthetic substitutes, such as hydroxyapatite (HA) or tricalcium 
phosphate based materials, also possess osteoconductive properties and present an alternative to autologous bone 
grafts. Nanocrystalline HA, for example the commercially available paste Ostim®, has been successfully used in 
the fields of oral, maxillofacial, and orthopaedic surgery, showing good biocompatibility and the potential to 
support bone formation without eliciting an inflammatory response8–14. As an injectable paste, Ostim® can be 
applied in a minimally invasive manner to completely fill irregular defects. Laschke et al. reported that the degra-
dation process of Ostim® enabled cellular migration into the augmentation material and thereby supported vas-
cularisation and facilitated bone formation14. Brandt et al. observed agglomerations of the Ostim® nanocrystals 
that became more dense over time, remaining embedded in bone and connective tissue without further resorp-
tion11. While single nanoparticles might provoke inflammatory responses and inhibitory effects15,16, agglomerates 
increased the fibronectin adsorption which influences osteoblast adherence17–19. The surface topography of HA 
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plays a critical role in bone regeneration. HA crystals in hard tissues have been reported to be nanoscale rod-like 
or plate-like crystals20. Nanostructured surfaces of implant materials have been shown to enhance cellular activity 
and induce bone formation14,16,21–24. We hypothesize that the HA content and particle size of the nanocrystalline 
HA paste may affect material behaviour with regard to resorption and bone formation and therefore the in vivo 
outcome. In our study, three HA pastes differing in HA content and particle sizes were evaluated. Based on pre-
liminary in vitro studies25, the following pastes were selected: a paste with a concentration of HA of 38% and rod 
shaped particles with a mean length of 40–60 nm (nHA-LC), a paste with a HA content of 48% and a similar mean 
particle length of 40–60 nm with a more elongated particle shape (nHA-HC) and the commercially available 
Ostim® with a HA content of 35%, rod shaped particles with reported average dimensions of 150 nm × 25 nm26.
The aim of this study was to compare the potential of two newly developed bone substitute materials to facili-
tate bone formation, with Ostim®, a commercially available product, and the “gold standard” autologous cancel-
lous bone, in an ovine defect model.
Results
Materials characterisation. X-ray powder diffraction (XRPD) was employed in order to evaluate the phase 
purity of the test materials. A full match with HA was obtained (full match with the JCPDS card 9–432) with no 
other phases detected (see Supplementary Fig. 1). The broad peak reflections of the patterns obtained for both 
nHA-LC and nHA-HC are characteristic of poorly crystalline phases and/or small crystallite size. XRD analysis 
was not performed on the Ostim® material as the information was readily available from the supplier and stated 
that it is a phase-pure hydroxyapatite. Thus, we can conclude that both commercially available and in house mate-
rials do not contain any other phase and appear to be stoichiometric hydroxyapatites.
Thermogravimetric analysis was performed in order to quantify water content of the non-commercial pastes 
(see Supplementary Fig. 2). A rapid weight loss up to the temperatures of ca. 400 °C was observed for both pastes 
characteristic of the water release from the surface and lattices of hydroxyapatite particles27. After this tempera-
ture no more weight loss was detected. Thus, it was possible to estimate the amount of water present in the mate-
rials at 38 wt% for nHA-LC and 48 wt% for nHA-HC, with the former comparable to that of Ostim® (35 wt%) and 
the latter having the highest ceramic loading among all the materials tested. Moreover, no further weight loss was 
detected after all water had been removed. This shows that materials are thermally stable in the range of temper-
atures tested, which can be used as further (indirect) evidence of the materials stoichiometry and phase purity28.
Transmission electron microscopy was used to visualise the materials constituent particles at the nano-level 
and estimate their particle size (see Supplementary Fig. 3). Surprisingly, Ostim® did not appear to consist of 
needle shaped nano-particles of 150 × 25 nm, as reported earlier in literature14,26. On the contrary, it comprised 
of two different particle types: (a) rod shaped ones with the dimensions of ca. 70 × 20 nm and (b) interconnected 
ribbon shaped particles of variable length sometimes exceeding 300 nm. The in-house (non-commercial) mate-
rials, comprising mostly of rod shaped nanoparticles with an average length of ca. 40–60 nm, slightly varied in 
the level of roundness, with the ones of nHA-HC being more elongated than that of nHA-LC. This variation may 
have originated from the preparation method and/or could have been a side effect of the scaling up process of 
material production.
Interestingly, it was observed that the resulting materials (nHA-LC and nHA-HC) also had different consisten-
cies and appearance: nHA-LC was more paste like, while nHA-HC more like a transparent gel. It was possible to 
concentrate the nHA-HC produced on a small scale up to nearly 50 wt% while preserving its injectability proper-
ties, whereas nHA-HC, produced at large scale, was hard to concentrate above ca. 40% as increasing the ceramic 
content led to a loss of its fluidic properties. It is out of the scope of this manuscript to discuss the differences in 
the rheological behaviour and optical properties of the pastes and their possible relation to a scale up process, and 
therefore this manuscript will focus on the in vivo performance of the materials.
Radiography results (x-ray, micro-CT). Animals were sacrificed at 6 months or 12 months after surgery. 
The x-ray images of the defects filled with the HA pastes Ostim®, nHA-LC and nHA-HC indicated that material 
was present in the defect area at both time points. The defect areas of the control group and of the autologous 
group were detectable after 6 and 12 months on x-ray images (Fig. 1). The reconstruction of the micro-CT eval-
uation after 6 months showed a non-bridging or cavity formation in the cortical area of the defects in all groups 
except the defects filled with nHA-HC (Fig. 2). After 12 months the control group, the autologous group and 
the defects filled with Ostim® showed a non-bridging or cavity formation at the defect sites, whereas the groups 
nHA-LC and nHA-HC showed a complete reconstruction of the cortical bone (Fig. 2). nHA-LC, nHA-HC and 
Ostim® were detectable in the micro-CT at both time points. The pastes, nHA-LC and Ostim® separated into par-
ticle units or agglomerates, whereas nHA-HC remained mainly compact in the form of a single large agglomerate 
and showed bone integration only in the periphery of this structure (Fig. 2).
After 6 months, 27% of the empty control group (3 out of 11), 17% of the autologous group (2 out of 12) and 
55% of the Ostim® filled defects (6 out of 11) presented a bridging, whereas 82% of the nHA-LC group (9 out of 
11) and 92% of the nHA-HC filled defects (11 out of 12) showed a bridging of the defect. After 12 months, bridg-
ing was detectable for 33% for the empty control group (4 out of 12), 25% for the autologous group (3 out of 12), 
42% for the Ostim® filled defects (5 out of 12), but for 75% of the nHA-LC group (9 out of 12) and 83% for the 
nHA-HC filled defects (10 out of 12).
Histologic evaluation. The margins of the drill holes and their original size were readily detectable in the 
histologic specimens (see Supplementary Fig. 4). The existing bone present at the edges of the defect stained 
a lighter shade of pink compared to the new bone tissue that had regenerated inside of the drill hole, which 
was darker and purple in colour. There were distinct differences between different regions of the defect area. 
While in the medullary compartment cancellous bone tissue was formed in an amount and in a quality that was 
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comparable to the pre-surgical state, in the cortical area bone regeneration was usually impaired. In the control 
group which received no bone substitute material at all, deep concave depressions were visible in the cortical 
bone. Additionally, in many cases the bony cortex was not completely continuous but was breached by canals that 
connected the bone marrow with the surrounding periosteal region, i.e. the defects were not completely bridged. 
This indicates that in the chosen animal model no final defect healing is achieved spontaneously, neither after 6 
nor after 12 month. Even when treated with autologous bone, depressions, canals and gaps were present in the 
cortical layer. Only very small remnants of the bone graft were still detectable in the augmented regions.
The three tested HA-pastes exhibited very different results in several aspects. The most obvious was the 
amount, size and size variation of the remaining agglomerates of HA-paste. In the Ostim® group many of these 
agglomerations formed numerous particles that had about the size of an osteon (200 μ m). In the nHA-LC group 
most of the agglomeration particles were of about the same size, but there were also a few much larger particles, 
often more than 5 mm in diameter. This trend was even more pronounced in the nHA-HC group where single 
particle agglomerations, significantly larger than in the nHA-LC group, were detectable, often filling the whole 
defect.
Concerning the regeneration of the cortical layer, Ostim® and nHA-LC exhibited results that were comparable 
to the control groups. The cortical areas showed depressions and canals connecting the marrow space with the 
soft tissue surrounding the scapula although not as severe and frequent as in the controls. In the nHA-HC group 
on the other hand the cortical bone overlaying the large agglomerations was more continuous, depressions less 
pronounced or absent and the prevalence of holes in the compact bone lower.
No great differences were seen in the osteoconductive properties of the bone substitutes. Most of the surfaces 
of all three materials were covered with thin layers of vital, newly formed bone, demonstrating their ability to 
enhance and promote bone regeneration. On those parts of the surfaces not covered with bone, very often signs 
of resorption could be seen. These occurred in the form of resorbing, multinucleated cells, resorption lacunae 
and more often discoloured seams that are characteristic of the cellular degradation of bone substitute materials.
Histological findings changed comparatively little between 6 and 12 months. Most prominent is the reduction 
of the size of particle agglomerations also indicating that resorption of HA-pastes is continuously proceeding over 
considerable periods of time.
Figure 1. Representative example of the surgical site with marks for the histological sectioning (X-ray, 
60 kV, 0.32 s, 6 months after augmentation): Five defects were placed at the caudal edge of the left scapula 
and filled in a randomised order with the 4 test substances while 1 was left empty. Every defect site was 
marked with a titanium pin. Images of the corresponding histological sections, stained with Levai-Laczko dye, 
are depicted on the right.
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Histomorphometric evaluation. Bone Substitute Volume/Tissue Volume. The BS.V/TV describes the per-
centage of bone substitute material in the cortical or medullary defect areas. Compared to Ostim®, a statistically 
significant increase in BS.V/TV was detected at 6 months in both regions of interest for nHA-LC (p < 0.001) as 
well as nHA-HC (p < 0.001). At 12 months, the BS.V/TV was increased in the medullary region for nHA-LC 
(p < 0.001) and nHA-HC (p < 0.001) compared to Ostim®. In the cortical region at 12 months elevated levels of 
BS.V/TV of defects filled with nHA-HC were detected compared to Ostim® (p < 0.001) and nHA-LC (p < 0.001) 
(Fig. 3).
Number and size of bone substitute particles. The nanoparticles of the three different pastes formed larger par-
ticle agglomerates, their size and number could then be determined on the histological sections. In the cortical 
region, nHA-LC showed the highest BS. Pa.N. per mm2 compared to Ostim® (p < 0.001 at 6 months, p < 0.015 
at 12 months) and nHA-HC (p < 0.001 at 6 and 12 months). In the medullary region at 6 months, a signifi-
cant decrease of nHA-HC BS.Pa.N/TV was found compared to Ostim® (p < 0.033) and nHA-LC (p < 0.003). At 
12 months, a decreased amount of nHA-HC BS.Pa.N/TV was measured compared to nHA-LC (p0.001) (Fig. 4a).
The BS.Pa.Ar. of all pastes showed a tendency to decrease from month 6 to month 12, indicating a certain 
break-down and resorption of the material (Fig. 4b). At 6 months, no significant difference in BS.Pa.Ar. could 
be defected in the cortical region. In the medullary region an increased nHA-HC particle agglomerate size was 
detected compared to Ostim® (p < 0.001) and nHA-LC (p < 0.001). At 12 months, the BS.Pa.Ar. of nHA-HC in 
Figure 2. Micro-CT reconstructions of representative defect sites 6 months (left) and 12 months (right) 
after implantation. Defects left empty or filled with autologous bone or Ostim® showed a non-bridging or 
cavity formation in the cortical region. nHA-LC and nHA-HC were able to bridge the defect site at the cortical 
area. A high amount of dense nHA-HC was found in the defect site.
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the cortical and medullary region was found to be significantly increased compared to Ostim® (p < 0.001 and 
p = 0.026, respectively) and nHA-LC (p < 0.001 and p = 0.028, respectively) (Fig. 4b).
Newly formed bone volume and the composite volume of bone substitute and newly formed bone in the regions of 
interest. At 6 months, no significant differences in nBV/TV were measured in the cortical region. In the medul-
lary region a reduced amount of nBV/TV was detected for the defects filled with nHA-HC compared to the empty 
control (p = 0.018), the autologous bone (p = 0.038) and Ostim® (p < 0.001). Also between the defects treated 
with Ostim® and nHA-LC a significant difference was found (p = 0.017) (Fig. 5a). At 12 months, a significant 
decrease in nBV/TV in the cortical region between defects augmented with nHA-LC and nHA-HC was detected 
(p = 0.011). In the medullary region defects filled with nHA-HC showed a decrease in nBV/TV compared to all 
other groups (p < 0.001) (Fig. 5a).
The highest amount of composite volume, which is the sum of volumes of newly formed bone and bone substi-
tute material, per TV was found at both time points and in both areas of interest in the defects filled with nHA-HC. 
Up to 97.1% (12 months, cortical region) of the region of interest treated with nHA-HC consisted of composite 
material (Fig. 5b). Defects filled with nHA-LC showed Co.V/ TV means in the cortical region of 82.1% (month 6) 
Figure 3. Bone substitute volume (BS.V.) per tissue volume (TV): percentage of the regions of interest that 
are filled with bone substitute material. Among the three HA-paste fillings, nHA-HC showed the highest and 
Ostim® the lowest BS.V/TV ratios at both time points in both areas of interest (*p-value < 0.05 compared to 
Ostim®).
Figure 4. (a) Number of bone substitute particle agglomerates (BS.Pa.N) per tissue volume (TV): In the 
cortical region, an increase in nHA-LC BS.Pa.N/TV was detected. In the medullary region at 6 months, a 
decrease in nHA-HC BS.Pa.N/TV was measured. (b) Average size of bone substitute particle agglomerates 
(BS.Pa.Ar) as measured in the region of interest in mm2 presented on a logarithmic scale. nHA-HC showed an 
increased agglomerate size with means ranging from 0.22 to 2.67 mm2, compared to the mean agglomerate sizes 
of nHA-LC and Ostim® ranging below 0.051 mm2 (*p-value < 0.05 compared to Ostim®).
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and 88.8% (month 12); and in the medullary region of 77.6% (month 6) and 73.1% (month 12). Defects aug-
mented with Ostim® resulted in Co.V/TV means in the cortical region of 56.8% (month 6) and 71.4% (month 12) 
and in the medullary region of 49.9% (month 6) and 58.6% (month 12) (Fig. 5b).
Soft tissue ingrowth-Periosteal void volume per TV. The PS.Vd.V/TV shows the percentage of soft tissue that has 
penetrated from the periosteal region into the defect area. In general, more soft tissue ingrowth was found in the 
cortical region compared to the medullary region. No significant difference was found in the medullary region 
between the groups at both time points. In the cortical region at 6 months, a significant decrease of soft tissue 
ingrowth was found for the defects filled with nHA-LC compared to the empty control group (p = 0.004), the 
autologous group (p = 0.034) and Ostim® (p = 0.006). Similarly, the defects augmented with nHA-HC showed 
a significant decrease in soft tissue ingrowth compared to the empty control (p = 0.002), the autologous group 
(p = 0.019) and Ostim® (p = 0.003). Also after 12 months, less soft tissue ingrowth was observed for defects filled 
with nHA-LC compared to the empty control (p = 0.001) and the autologous group (p = 0.010). Defects filled 
with nHA-HC showed a decreased soft tissue ingrowth compared to the empty control (p < 0.001), the autologous 
Figure 5. (a) Newly formed bone volume (nBV) per tissue volume (TV): Comparable results were found 
between the defect fillings at both regions of interest and both time points, except the defects filled with 
nHA-HC, which showed a lower bone bone volume per TV in the medullary region. (b) Defects filled with 
Ostim®, nHA-LC and nHA-HC showed an increased composite volume (Co.V) per tissue volume (TV) 
compared to the autologous group at both time points in the medullary region (p < 0.001). In the cortical 
region, a significant increase at both time points in Co.V/TV between defects filled with nHA-LC and nHA-HC 
and the autologous group (p ≤ 0.018) were found (*p-value < 0.05 compared to autologous control).
Figure 6. Periosteal void volume (Ps.Vd.V) per tissue volume (TV) presenting the soft tissue ingrowth into 
the defect site. Very limited soft tissue ingrowth was detected in the medullar region for all treatment groups 
and at both time points. In contrast, soft tissue ingrowth was found in the cortical region when the defects 
were filled with Ostim®, autologous bone or left empty. nHA-HC and nHA-LC showed a decreased soft tissue 
ingrowth at both time points (*p-value < 0.05 compared to autologous control).
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group (p = 0.001) and Ostim® (p = 0.040) (Fig. 6). No significant differences were detected between Ostim® and 
the control groups or between nHA-LC and nHA-HC.
A summary of the histomorphometric evaluation can be found in Supplementary Table 1 (cortical region) and 
Supplementary Table 2 (medullary region).
Discussion
It has been reported that sheep present a valuable model for human bone turnover and remodelling. It was 
demonstrated that the ovine bone ingrowth and mineral acquisition into porous-coated implants was comparable 
to that of humans29. Additionally, the ovine weight and bone dimensions are more similar to humans than other 
animal models and furthermore, aged sheep have been also shown as suitable model for human osteopenic and 
osteoporotic bone30,31. While the x-ray evaluation of the bones confirmed that the defects were placed at the same 
locations of the left scapula, the micro-CT showed that only the upper cortical bone and medullary regions were 
involved, whereas the lower cortical region remained intact. The empty defects resulted in non-bridging (average 
of 70% of the defects) or cavity formation, suggesting that an adequate model and time points were chosen.
HA is widely used in the clinics and has been reported as a biocompatible and osteoconductive bone sub-
stitute material8,9,11,14,32,33. Ostim®, a nanoparticular HA aqueous paste, has been described as bone-inducible 
paste. Several publications observed that Ostim® particles were not fully resorbed 12 weeks post-surgery9,11,12,34. 
In general all HA pastes used in this study were shown to support bone formation. 12 months post-surgery the 
three HA pastes were, to varying degrees, detectable in all defects. The HA content of the pastes related to the 
amount of BS.V/TV, and Co.V/TV. However, as the particle size and shape also varies among the three pastes, the 
performance of the pastes cannot be merely attributed to their HA content. We observed nanoparticle agglom-
erates of various sizes for all three pastes. nHA-HC agglomerates presented mean sizes ranging from 0.22 mm2 
to 2.67 mm2. In the medullary region, nHA-LC agglomerates showed mean sizes of 0.051 mm2 after 6 months 
and 0.017 mm2 after 12 months. The mean agglomerate size of Ostim® in the medullary region was 0.008 mm2 
after 6 months and 0.006 mm2 after 12 months. These differences in agglomeration behaviour may explain the 
significantly quicker resorption of Ostim® compared to nHA-LC that has a similar HA content. The BS.Pa.N/TV 
evaluation underlined the particle aggregation of the nHA-HC paste resulting in a very low particle number 
but large particle size. The trend of BS.Pa.N/TV increase along with the tendency of a mean BS.Pa.Ar. decrease 
for nHA-LC and Ostim® in the medullary region from month 6 to 12 indicated the break-down of the particle 
agglomerates into smaller agglomerate subunits. The defects filled with Ostim® and autologous bone resulted 
in a cavity formation and a low ratio of bridging defects (average of 48% for Ostim® and 21% for autologous 
bone). In contrast, defects filled with nHA-LC and nHA-HC showed a cortical bone formation with an average 
bridging ratio of 78% (nHA-LC) and 88% (nHA-HC), respectively. This effect was observed in the micro-CT 
evaluation and confirmed by the Ps.Vd.V/TV results, showing soft tissue ingrowth in the defect sites. Dau et al. 
created mono cortical critical size bone defects in minipigs that were filled with the two nanoparticular HA pastes 
Ostim®, NanoBone® or the natural bone substitute material Bio-Oss®, which is derived from the mineral portion 
of bovine bone. While after 8 months, Ostim® showed the least amount of residual material at the defect sites, no 
differences in new bone formation or soft tissue ingrowth was detected between the tested groups. They recom-
mended NanoBone® or Bio-Oss® for use in defects that require stability of the bone35. In contrast to Dau et al., 
our study detected an increased soft tissue ingrowth in the Ostim® group compared to the other HA pastes. Based 
on our findings nHA-LC should be chosen for stable bone integration.
Interestingly, autologous bone grafts failed to improve bone formation or decrease soft tissue ingrowth, giving 
comparable results to the empty control. Bone grafts undergo extensive remodelling and resorption during the 
first year. Dependent on the nature of the grafted material and implantation site, various autologous bone resorp-
tion rates have been reported36. A 29% resorption rate of autologous bone grafts from the iliac crests used for 
sinus floor augmentation was observed after 3 months37. Van der Meij et al. reported the presence of approxi-
mately 30% of autologous bone graft from the iliac crest for cleft lip and palate treatment after 1 year38. Autologous 
bone blocks for horizontal ridge augmentation lost 28% of its volume during 6 months39. In our study a low 
amount of the autologous cancellous bone was detectable at both time points, indicating a fast resorption of the 
grafted material. The fast resorption of the autologous bone graft may explain the similar results to the empty 
defects. Several publications reported a size-dependent cytotoxic effect of nanoparticles in vitro and in vivo when 
administering particle suspensions40–43. Clinical studies evaluating the suitability of Ostim® as a bone-filling 
matrix reported good bone induction with limited or no side effects44–48. Huber et al. reported that biopsy anal-
ysis showed good bone formation without inflammatory reactions, osteofibrosis or osteonecrosis48. In this study 
we observed good bone regeneration for all three HA pastes without any inflammatory reaction, osteofibrosis 
or osteonecrosis. The liquid phase of the water-based HA pastes can decrease over time, which could explain 
the formation of dense particle agglomerates11. Therefore, the previous studies evaluating monodisperse particle 
solution might not represent the observed in vivo paste behaviour.
In this study we observed a strong correlation between HA content, the size of the particle agglomerates with 
the amount of newly formed bone tissue and defect bridging. While a high HA content of 48 wt% with larger par-
ticle agglomerates supported defect bridging, less newly formed bone tissue was obtained within the defect site. 
This is probably caused by the fact that large particle agglomerates leave less space for the formation of new bone. 
On the other side, a lower HA content of 35 wt% (Ostim®) and 38 wt% (nHA-LC), respectively, was correlated 
with smaller particle agglomerates, an increased amount of newly formed bone tissue within the defect but also a 
reduced defect bridging ratio. The impact of particle agglomeration behaviour must be examined in more detail 
in further studies.
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Conclusion
In this preclinical study, three bone graft pastes of different HA concentrations and particle sizes were compared 
to treatment of defects with autologous bone and empty defects. Bone regeneration and growth but incomplete 
defect healing was observed in the empty control group and by treatment with autologous bone. However, a cav-
ity at the defect site was visible. While the higher concentrated (48 wt%) nHA-HC agglomerated and supported 
bone formation only on the outer surface of the material, Ostim® (35 wt%) degraded the quickest and could not 
fill the defect for a sufficient period of time to allow for a complete cortical bone bridging. This was similar to the 
autologous bone filling where a cavity at the defect site, an increase in soft tissue ingrowth and a low bridging rate 
were observed. We suggest that the agglomeration behaviour presents a critical parameter for nanoparticular HA 
pastes due to their influence on material resorption and bone formation. nHA-LC (38 wt%) seemed to have the 
best combination of characteristics that lead to good bone regeneration, reduced soft tissue ingrowth, had a high 
defect bridging rate and optimal particle agglomeration size, while keeping in mind the limitations of animal 
studies.
Materials and Methods
Materials preparation and characterisation. Commercially available Ostim® was obtained from 
Heraeus Kulzer, Germany. Nano-hydroxyapatite (nHA) was prepared as previously described49. In brief, aqueous 
solutions of calcium chloride and potassium phosphate monohydrate were fed into the inlets of either large or 
small scale NETmix reactors at a molar ratio of 1.67, or 5:350, under controlled pH of 11–12 using potassium 
hydroxide (all reagents from Sigma-Aldrich, Spain). Resultant slurries were further concentrated to viscous 
pastes/gels of ca. 38 and 48 wt% and were given codes nHA-LC for material prepared in a large scale reactor and 
nHA-HC for material from a small scale reactor, respectively.
Thermogravimetric analysis (TGA) was performed on nHA-LC and nHA-HC materials to quantify the con-
centration of water and ceramics (nHA) in the systems. TGA was carried out using a PerkinElmer Pyris 1 ther-
mogravimetric analyser. Heating was performed in a platinum crucible in nitrogen flow (20 cm3·min−1) at a rate 
of 10 °C min−1 from 30 °C up to 1000 °C. Proportions of the materials were dried at 60 °C and further ground for 
performing phase analysis using x-ray powder diffraction (XRPD) method.
Aliquots of the pastes as well as Ostim® were dissolved in distilled water and dispersed onto a holey carbon 
film supported by a 300 mesh copper grid for particle size evaluation using a transmission electron microscope 
(TEM) JEOL JEM-3010 with a LaB6 electron gun at an accelerating voltage of 300 kV.
X-ray powder diffraction (XRPD) patterns were acquired using a Siemens D5000 Diffractometer operating at 
40 kV and 40 mA with Cu Kα radiation. Analysis of the obtained patterns was carried out using X’Pert HighScore 
Plus software, and stripping of the Kα -2 component was carried out when appropriate.
Ethical conduct of research. The study was approved by the local Thuringia State Office ethical committee 
(“Thüringer Landesamt für Verbraucherschutz”) and was conducted in accordance with the principles of the 1964 
Declaration of Helsinki.
Animals and anaesthesia. For this study, 24 adult (age of 2-3 years) female land merino sheep that during 
their life had given birth at least 1-2 times were housed in a freestall barn, fed with hay and allowed to drink 
water ad libitum. The study was approved by the local ethical committee for animal experiments (see chapter 
Ethical conduct of research). Haematological and parasitological examinations were performed prior to the study. 
Animals were operated in two groups in the late autumn. General anaesthesia was induced by an intravenous 
administration of 0.1 mg/kg Diazepam, 4.4 mg/kg Ketamin and 0.1 mg/kg Xylazin. After induction, the animals 
were intubated and connected to a semi-open anaesthesia system with an isoflurane concentration of 1.0–1.5 
volume% and an oxygen supply of 2 l O2/min. The animals received a pre-operative systemic antibiotic (3 ml/50 kg 
Veracin-Compositum i.m.) as well as the analgeticum Rimadyl® (Pfizer, 1 ml/35 kg i.v.).
Surgical procedure, material application and post-operative medication. A longitudinal incision 
along the caudal border of the left scapula was made and the border was exposed by sharp dissection. Using a tre-
phine drill, five defects with a diameter and depth of 8 mm were created, leaving a 5 mm bony bridge in between 
each defect51. The longitudinal axis of the drill holes was oriented perpendicular to the lateral face of the scapula. 
The bony cylinders from the drill holes were preserved for autologous bone grafting. Titanium pins were placed 
close to the periphery of the holes to mark the exact location of the defect areas. One defect remained empty and 
served as a control. The other defects were filled with one of four materials: (1) autologous bone graft, (2) the 
commercially available Ostim® with a HA content of 35 wt%, (3) injectable paste with a concentration of 38 wt% 
HA-crystals (nHA-LC) and (4) paste with a high concentration of 48 wt% HA-crystals (nHA-HC) (Fig. 1). The 
five groups were randomised to the defect sites for each animal prior to the procedures. The surgical site was 
closed in multiple layers using Monocryl 3-0 suture material. The animals received Rimadyl® 1 ml/35 kg s.c. five 
days post-operatively. Twelve animals were euthanised after either 6 or 12 months by the administration of T 61® 
i.v.
Histology and sample preparation. The scapulae were removed and fixed in buffered formalin. Overview 
radiographic images were produced to ascertain the exact location of the augmentation sites. Blocks, each of 
them containing one of the defects were dissected using a diamond coated band saw (EXAKT Apparatebau, 
Norderstedt, Germany) by cutting precisely in between the drill holes as visible on the radiograph. These blocks 
were subjected to micro-CT (μ CT) analysis (see section “Micro-CT analysis”). After the μ CT scan the speci-
men blocks were dehydrated, embedded in plastic and then undecalcified thin sections were produced using 
the method of Donath52. Histologic specimens were stained with Levai-Laczko dye and photographed with an 
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Olympus BX61VS scanning microscope (Olympus DotSlide system 2.4; Olympus, Tokyo, Japan) at a resolution 
of 0.321 μ m/pixel.
Micro-CT analysis. The samples were scanned in a SCANCO μ CT 50 at 90 kV with an isotropic resolution of 
17.2 μ m. The scans were exported as 16 bit DICOM image stacks. Based on the micro-CT evaluation the closure of 
the defects was categorised as “non-bridging” (leaving a continuous opening in the cortical bone connecting the 
medullary cavity with the periosteal area) or “bridging” when the continuity of the cortical bone was completely 
restored and no opening remained.
Histomorphometric analyses. The histological images were downsampled to 25% (1.283 μ m/pxl) and 
then automatically segmented using Definiens Developer XD 2.1 (Definiens AG, Munich, Germany). Errors in 
segmented images were corrected manually using Photoshop CS 4 (Adobe Systems Inc., San Jose, CA, USA). The 
corrected images were then measured in Definiens Developer XD 2.1. A quadtree segmentation, in which square 
objects are quartered until they fulfil set homogeneity criteria, was applied to the images. The resulting square 
objects were first classified in a very rough manner to determine the colour balance of the individual image. The 
background (soft tissue) was classified using a very conservative threshold and then grown into surrounding 
background using a less restrictive threshold. Bone in the remaining area was classified using differences in the 
colour layers. Bone objects which were not bordered by other bone objects on at least two sides were declassified 
to remove potential misclassified bone objects. In the resulting segmented bone, the mean difference between the 
red and green layers were measured and used to calculate the threshold for a more accurate segmentation. Bone 
and the unclassified area around it was thresholded using this calculated threshold on the pixel level. The border 
between bone and background was smoothed using alternating pixel based growing and shrinking constrained 
by surface tension. Small objects completely surrounded by another class were added to the surrounding class. 
The border was further improved by allowing it to shift position slightly if this increased the difference between 
the separated classes in the area. The segmentation was exported for manual correction. The regions of interest 
were selected before the correction. The cortical region of interest was defined as the area between the boundaries 
of the drill hole in the cortical bone and the periosteal and endosteal margins. The medullary region of interest 
was located 1 mm beneath the cortical region of interest, was oriented parallel to it and had a height of 1 mm. The 
medullary region of interest also spanned the whole breadth of the drill hole and lay solidly within the marrow 
space.
As the substitute materials could not be reliably distinguished automatically these were classified entirely 
manually. The corrected images were then measured in Definiens. The areas of newly formed bone (nBV), back-
ground or soft tissue (Vd.V), substitute material (BS.V) and the complete region of interest (TV; tissue volume) 
were measured. Also the sizes of the individual particle agglomerates (BS.Pa.V) and their number (BS.Pa.N) were 
determined. From these primary measurements the following parameters were calculated: The percentage of 
bone substitute material in the regions of interest (BS.V/TV), the average size of particle agglomerates (BS.Pa.Ar) 
in mm2, the number of bone substitute particle agglomerates per mm2 (BS.Pa.N/TV), the percentage of newly 
formed bone in the regions of interest (nBV/TV), the percentage of the composite of newly formed bone plus 
bone substitute material (Co.V/TV), the percentage of the region of interest filled with soft tissue that had grown 
from the periosteal region into the defect area (Ps.Vd.V; Periosteal void volume).
Statistical analysis. All animals were included in the final analysis; one defect site (6 months, Ostim®) was 
excluded due to faulty drilling. Two other defects (6 months, empty control and autologous) were excluded from 
the bridging/non-bridging analysis due to later micro-CT reconstruction problems. For inference, multiple linear 
mixed models for all independent variables were built using treatment as independent variable and animal ID as a 
random factor. We then proceeded to calculate Tukey-type post-hoc tests for treatment effect53. All computations 
were done using R version 3.2.354. Statistical Graphs were created using ggplot255.
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